14.11.2012, 17:15 - HZI Colloquium - Wissenschaftlich
Werner Scheuer "Application of imaging in the drug development process: advantages and limitations from an industrial perspective"
Different imaging modalities are used to monitor disease progression and to analyze therapeutic efficacy in preclinical cancer models. Each of these different methods has their advantages and limitations and no single imaging modality provides the tool to address all the questions arising in the drug development process. Fluorescence and Bioluminescence imaging are excellent technologies for preclinical research because of its simplicity, fast scanning times, non-hazardous radiation and non-radioactive isotopes. The application of different near-infrared labels and “smart probes” enables multiplexing and allows simultaneous measurements of fluorescence and bioluminescence. We will demonstrate the utility of different in vivo and ex vivo imaging modalities for monitoring primary tumor growth, metastasis and angiogenesis. In addition, we will summarize the advantages of optical imaging for the combined measurement of pharmacodynamics and pharmacokinetics in cancer xenografts. Excellent reviews describe the application of non-invasive imaging in the preclinical setting however, only limited data are available demonstrating how optical imaging has improved the drug development process. Examples are given how this modality has supported project-related decisions.